These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19389498)

  • 21. Thalidomide in the treatment of multiple myeloma.
    Kastritis E; Dimopoulos MA
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):681-99. PubMed ID: 18070713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
    Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib plus dexamethasone is highly effective in relapsed and refractory myeloma patients but responses are short-lived.
    Corso A; Varettoni M; Mangiacavalli S; Zappasodi P; Pica GM; Algarotti A; Pascutto C; Lazzarino M
    Eur J Haematol; 2009 Nov; 83(5):449-54. PubMed ID: 19519727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.
    Mehta J; Singhal S
    Bone Marrow Transplant; 2007 Dec; 40(12):1101-14. PubMed ID: 17680020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series.
    Wolf J; Richardson PG; Schuster M; LeBlanc A; Walters IB; Battleman DS
    Clin Adv Hematol Oncol; 2008 Oct; 6(10):755-60. PubMed ID: 18997666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple myeloma: chemotherapy or transplantation in the era of new drugs.
    Palumbo A; Rajkumar SV
    Eur J Haematol; 2010 May; 84(5):379-90. PubMed ID: 20345446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status of autologous hematopoietic stem cell transplantation in myeloma.
    Mehta J; Singhal S
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S28-S34. PubMed ID: 18724294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
    Berenson JR; Yellin O; Patel R; Duvivier H; Nassir Y; Mapes R; Abaya CD; Swift RA
    Clin Cancer Res; 2009 Feb; 15(3):1069-75. PubMed ID: 19188182
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.
    Hovenga S; Daenen SM; de Wolf JT; van Imhoff GW; Kluin-Nelemans HC; Sluiter WJ; Vellenga E
    Ann Hematol; 2005 May; 84(5):311-6. PubMed ID: 15605244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib.
    Sood R; Carloss H; Kerr R; Lopez J; Lee M; Druck M; Walters IB; Noga SJ
    Am J Hematol; 2009 Oct; 84(10):657-60. PubMed ID: 19731393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
    Srikanth M; Davies FE; Wu P; Jenner MW; Ethell ME; Potter MN; Shaw BE; Saso RM; Dines S; Morgan GJ
    Eur J Haematol; 2008 Dec; 81(6):432-6. PubMed ID: 18691254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
    Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thalidomide and lenalidomide in multiple myeloma.
    Mazumder A; Jagannath S
    Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
    Bao L; Lu XJ; Zhang XH; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(26):1829-31. PubMed ID: 19040018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frontline treatment in elderly patients with multiple myeloma.
    Facon T; San Miguel J; Mateos MV; Hulin C
    Semin Hematol; 2009 Apr; 46(2):133-42. PubMed ID: 19389497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
    Catley L; Tai YT; Chauhan D; Anderson KC
    Drug Resist Updat; 2005 Aug; 8(4):205-18. PubMed ID: 16019253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lenalidomide in multiple myeloma.
    Sirohi B; Powles R
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1559-70. PubMed ID: 19895240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
    Richardson PG; Laubach J; Mitsiades C; Schlossman RL; Doss D; Colson K; McKenney ML; Noonan K; Warren DL; Ghobrial IM; Munshi NC; Anderson K
    Oncology (Williston Park); 2010 Mar; 24(3 Suppl 2):22-9. PubMed ID: 20518367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives.
    Jakubowiak A
    Semin Hematol; 2012 Jul; 49 Suppl 1():S16-32. PubMed ID: 22727389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.